$LQDA

JEFFS ROGER sold $2.5M of LQDA

JEFFS ROGER (Chief Executive Officer) sold 35,249 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $2.52M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · JEFFS ROGER
Published Jul 15, 2026, 12:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest actionable element is the specific trade size, price range, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as a routine 10b5-1 sale, with limited fundamental implications, but it can marginally influence short-term sentiment.

03

What to watch

The filing does not disclose reasons for the sale, and the weighted-average price range ($71.39 to $71.52) suggests execution around prevailing market levels rather than a distressed sale.

Relevance 5/10Novelty 4/10Timing: SEC Form 4 filed 2026-07-14 for sales executed 2026-07-13

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reporting CEO Jeffs Roger’s open-market sale of shares.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia CEO Jeffs Roger sold 35,249 shares in open-market trades at about $71.51, per a newly filed SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless paired with other company-specific catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but the trades are explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific insider activity without sector-wide information.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of reduced confidence or liquidity needs, so traders may still watch for follow-on selling patterns.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Jeffs Roger

    CEO and director reporting the sale of shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.